Key facts
- HistoIndex’s last known valuation is $18.9M (Jun 2021).
- It has raised $12.3M; the latest was Later Stage VC ($6.8M) in May 2025.
- Notable investors include SEEDS Capital, Agency for Science, Boon Koh, Oversea-Chinese Banking Corporation, SNS HOLDINGS PTE. LTD. — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for HistoIndex
- ·The full record, as it builds
Funding rounds
No funding rounds for HistoIndex are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HistoIndex
Developer of a digital pathology platform designed to improve the diagnosis of chronic liver conditions. The company's platform offers stain-free, multi-dimensional, quantitative imaging for visualizing and staging fibrosis, enabling medical professionals to accelerate precision diagnosis and therapeutic development.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2010
- Employees
- 28
- Website
- histoindex.com/
- Ownership
- Privately Held (backing)
HistoIndex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HistoIndex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HistoIndex in its N-PORT filings yet. We sweep new filings monthly.